About this episode
Ruth Alexander speaks to patients about their experiences of weight-loss drugs.
The new class of drugs impact appetite, making you feel full sooner, and slowing the rate at which your stomach empties. Known as GLP-1 medications, studies suggest that patients can lose 10% or even up to 25% of their body weight depending on which drug they use. For many who have struggled with obesity and obesity related disease the drugs have the potential to transform their health.
However some patients have struggled with the side effects of the drugs and the manufacturers’ own studies indicate that if people stopping taking them, much of the weight lost is regained, making them drugs for life for some.
Ruth Alexander speaks to Professor of Cardiometabolic Medicine, Naveed Sattar, at Glasgow University who is Chair of the UK government’s obesity mission. He explains how these drugs work and the potentials costs and savings for the National Health Service, or NHS. Adrienne Bitar, historian at Cornell University in New York, is the author of ‘Diet and the Disease of Civilization’, a study of diet books of the 20th century. She explains the ideas diet culture is built on. And Ruth asks Gary Foster, Chief Scientific Officer at WeightWatchers, what these weight-loss drugs will mean for the multi-billion-dollar diet industry.
Presented by Ruth Alexander.
Produced by Beatrice Pickup.
Image: Michelle Herum in Denmark who currently uses a weight loss drug. Credit: Hanne Juul/BBC)
Get every episode summarized
Each time The Food Chain publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
